Bosi A, De Majo E, Guidi S, Parri F, Saccardi R, Vannucchi A M, Fanci R, Ferrini P R
Cattedra e Divisione di Ematologia, Università degli Studi, Ospedale di Careggi, Firenze, Italy.
Haematologica. 1990 Mar-Apr;75(2):109-12.
Polyspecific iv immunoglobulins (IVIG) are routinely used to prevent cytomegalovirus (CMV) infections in bone marrow transplant recipients; however, the plasma disappearance pattern of CMV-specific antibodies after administration of this product remains unclear because conflicting kinetic data have been reported previously. We studied the half-life of CMV-specific antibodies in 9 patients undergoing bone marrow transplantation after administration of 500 mg/kg of a conventional polyspecific IVIG preparation (Sandoglobulin, Sandoz Pharmaceuticals). Eight serial blood samples were drawn for kinetic evaluation after the dose. The titer of CMV-specific antibodies in the sample was determined by the FIAX method, and the decay curves of CMV-specific antibodies were analyzed kinetically using model-independent method. The 9 kinetic curves showed that a titer above 20 Fiax units was maintained for only 7 days after dosing. The mean half-life of CMV-specific antibodies was 5.6 days (range 3.5 to 12.5 days), indicating that their elimination rate was much faster than that found in several other studies. Our results suggest that the optimal dosing interval for these products is around 1 week in bone marrow transplant recipients.
多特异性静脉注射免疫球蛋白（IVIG）通常用于预防骨髓移植受者的巨细胞病毒（CMV）感染；然而，此前报道的动力学数据相互矛盾，该产品给药后CMV特异性抗体的血浆消失模式仍不清楚。我们研究了9例接受骨髓移植的患者在给予500mg/kg传统多特异性IVIG制剂（Sandoglobulin，山德士制药公司）后CMV特异性抗体的半衰期。给药后采集8份系列血样进行动力学评估。采用FIAX法测定样本中CMV特异性抗体的滴度，并采用非模型依赖方法对CMV特异性抗体的衰减曲线进行动力学分析。9条动力学曲线显示，给药后CMV特异性抗体滴度高于20 Fiax单位仅维持7天。CMV特异性抗体的平均半衰期为5.6天（范围3.5至12.5天），表明其清除率比其他几项研究中发现的要快得多。我们的结果表明，在骨髓移植受者中，这些产品的最佳给药间隔约为1周。
